News

Catch up on key FDA approvals, major trial updates, and critical clinician insights from the last 3 months.

A review of 9 novel drugs approved by the US Food and Drug Administration during the second quarter of 2026.

Exagamglogene autotemcel (Casgevy) is now the first CRISPR-based gene-editing therapy to reach this age group in either condition.

Catch up on key FDA approvals, major trial updates, and critical clinician insights from the last 3 months.

A roundup of key FDA approvals, pipeline advances, and updated guidelines shaping allergy and HAE care in the first half of 2026.

This interview at the SDPA Summer Conference highlights key myths and how to address them as a clinician in dermatology.

Catch up on the nephrology headlines you missed in June 2026.

A review of 22 novel drugs approved by the US Food and Drug Administration during the first half of 2026, with links to coverage from MJH Life Sciences publications.

Catch up on FDA approvals, trial readouts, and key clinician insights across the cardiology specialty.

FDA epinephrine updates, phase 3 HAE data on lonvo-z, and new food allergy prevention research from April through June 2026.

Catch up on major trial results, groundbreaking FDA decisions, and key clinician insights from major endocrinology conferences.

June 2026 pulmonology news includes conversations with experts at the ATS and APAPP conferences, and cytisinicline's CRL.

HAE gene editing, peanut patch trials, CSU sequencing, and EAC 2026 highlights in this allergy/immunology roundup for clinicians.

New AD biologic data highlight early systemic treatment, durable itch control, and improved pediatric growth—shifting goals beyond skin clearance.

Ersodetug Shows Hypoglycemia Reduction Trends, Target Engagement in Phase 3 cHI Trial

This episode covers the recent commercial availability of the Pivot patch pump and the upcoming 7-day bolus patch from CeQur.

The status was granted off of data from Swedish snus — a smokeless tobacco product with similar use topography, nicotine content, pH, and systemic nicotine exposure.

Frieden shares practical tips on repurposing topical timolol and sirolimus for pediatric skin conditions.

Abivax’s ABTECT Part 2 showed Week 44 responses and safety consistency with obefazimod in refractory UC patients.

Blumenthal discusses his presentation at the 10th Annual Heart in Diabetes meeting, in which he compared the current US and European dyslipidemia guidelines.

Gideon Hirschfield, FRCP, PhD, discusses phase 2b results from VISTAs, evaluating volixibat in PSC

Rajani Katta, MD, on navigating the diet-skin connection: evidence, myths, and clinical ownership.

FDA sends fresh CRL for Unicycive’s OLC; manufacturing inspection delays approval, while data support a lower pill-burden phosphate binder.

Diabetes Dialogue cohosts Diana Isaacs, PharmD, and Natalie Bellini, DNP, cover recent data released by Eledon regarding tegoprubart for type 1 diabetes.

FDA approves steroid-free roflumilast cream for plaque psoriasis in children age 2+, bringing once-daily option for sensitive areas.

The FDA has approved veligrotug-vvze for thyroid eye disease regardless of activity or duration.

Ersodetug showed target engagement and hypoglycemia reduction trends in phase 3 cHI study but missed primary endpoints in SunRIZE trial.

Heather O'Connell, PA-C, an allergy and asthma PA, describes how she uses clinical research and structured follow-up to shift patient thinking about the nose-lung connection, and why APPs bring a distinct advantage to that conversation.